{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:18:52Z","timestamp":1788556732721,"version":"build-2803163510"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA046030"],"award-info":[{"award-number":["R21 DA046030"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA046345"],"award-info":[{"award-number":["P30 DA046345"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["1R13MH132238"],"award-info":[{"award-number":["1R13MH132238"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-024-05519-2","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T22:39:10Z","timestamp":1737412750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7948-2050","authenticated-orcid":false,"given":"Alejandra","family":"Pulido-Saavedra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6452-9833","authenticated-orcid":false,"given":"Henrique Nunes Pereira","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8803-5384","authenticated-orcid":false,"given":"Tiago Paiva","family":"Prudente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9791-1115","authenticated-orcid":false,"given":"Razi","family":"Kitaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7802-8740","authenticated-orcid":false,"given":"Eric J.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2084-1798","authenticated-orcid":false,"given":"Colleen","family":"Fogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-4846","authenticated-orcid":false,"given":"Melissa C.","family":"Funaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-7412","authenticated-orcid":false,"given":"Jeremy","family":"Weleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-3518","authenticated-orcid":false,"given":"Anahita Bassir","family":"Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5568-9878","authenticated-orcid":false,"given":"Gustavo A.","family":"Angarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"9","key":"5519_CR1","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1021\/acschemneuro.0c00741","volume":"12","author":"TT Joseph","year":"2021","unstructured":"Joseph TT, Bu W, Lin W, Zoubak L, Yeliseev A, Liu R et al (2021) Ketamine metabolite (2R,6R)-Hydroxynorketamine interacts with \u00b5 and \u03ba opioid receptors. ACS Chem Neurosci 12(9):1487\u20131497","journal-title":"ACS Chem Neurosci"},{"issue":"16","key":"5519_CR2","doi-asserted-by":"publisher","first-page":"e836","DOI":"10.1161\/CIR.0000000000000958","volume":"143","author":"C Dezfulian","year":"2021","unstructured":"Dezfulian C, Orkin AM, Maron BA, Elmer J, Girotra S, Gladwin MT et al (2021) Opioid-Associated out-of-hospital cardiac arrest: distinctive clinical features and Implications for Health Care and public responses: A Scientific Statement from the American Heart Association. Circulation 143(16):e836\u2013e70","journal-title":"Circulation"},{"issue":"1","key":"5519_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","volume":"87","author":"J Bell","year":"2020","unstructured":"Bell J, Strang J (2020) Medication treatment of opioid Use Disorder. Biol Psychiatry 87(1):82\u201388","journal-title":"Biol Psychiatry"},{"issue":"4","key":"5519_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","volume":"44","author":"K Rasmussen","year":"2019","unstructured":"Rasmussen K, White DA, Acri JB (2019) NIDA\u2019s medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology 44(4):657\u2013659","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"5519_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","volume":"69","author":"N Wilson","year":"2020","unstructured":"Wilson N, Kariisa M, Seth P, Smith Ht, Davis NL (2020) Drug and opioid-involved overdose deaths - United States, 2017\u20132018. MMWR Morb Mortal Wkly Rep 69(11):290\u2013297","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"5519_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMsr1706626","volume":"377","author":"ND Volkow","year":"2017","unstructured":"Volkow ND, Collins FS (2017) The role of Science in addressing the Opioid Crisis. N Engl J Med 377(4):391\u2013394","journal-title":"N Engl J Med"},{"key":"5519_CR7","doi-asserted-by":"crossref","unstructured":"Jones G, Ricard JA, Lipson J, Nock MK (2022) Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep. 12(1)","DOI":"10.1038\/s41598-022-08085-4"},{"key":"5519_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1037\/1064-1297.3.4.344","volume":"3","author":"LA Parker","year":"1995","unstructured":"Parker LA, Siegel S, Luxton T (1995) Ibogaine attenuates morphine-induced conditioned place preference. Exp Clin Psychopharmacol 3:344\u2013348","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1\u20132","key":"5519_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0006-8993(94)90948-2","volume":"657","author":"SD Glick","year":"1994","unstructured":"Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW Jr. et al (1994) Effects of Iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 657(1\u20132):14\u201322","journal-title":"Brain Res"},{"issue":"8\u20139","key":"5519_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1472-8206.1992.tb00127.x","volume":"6","author":"B Franc\u00e9s","year":"1992","unstructured":"Franc\u00e9s B, Gout R, Cros J, Zajac JM (1992) Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. Fundam Clin Pharmacol 6(8\u20139):327\u2013332","journal-title":"Fundam Clin Pharmacol"},{"key":"5519_CR11","doi-asserted-by":"publisher","first-page":"1183740","DOI":"10.3389\/fpsyt.2023.1183740","volume":"14","author":"R Zafar","year":"2023","unstructured":"Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S et al (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Front Psychiatry 14:1183740","journal-title":"Front Psychiatry"},{"key":"5519_CR12","first-page":"89","volume":"105","author":"C Lavaud","year":"2017","unstructured":"Lavaud C, Massiot G (2017) The Iboga alkaloids. Prog Chem Org Nat Prod 105:89\u2013136","journal-title":"Prog Chem Org Nat Prod"},{"key":"5519_CR13","doi-asserted-by":"publisher","first-page":"100025","DOI":"10.1016\/j.addicn.2022.100025","volume":"3","author":"FR Mendes","year":"2022","unstructured":"Mendes FR, Costa CS, Wiltenburg VD, Morales-Lima G, Fernandes JAB, Filev R (2022) Classic and non-classic psychedelics for substance use disorder: a review of their historic, past and current research. Addict Neurosci 3:100025","journal-title":"Addict Neurosci"},{"issue":"2","key":"5519_CR14","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","volume":"32","author":"B Kelmendi","year":"2022","unstructured":"Kelmendi B, Kaye AP, Pittenger C, Kwan AC (2022) Psychedelics Curr Biol 32(2):R63\u2013r7","journal-title":"Psychedelics Curr Biol"},{"issue":"11","key":"5519_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","volume":"42","author":"LR Aleksandrova","year":"2021","unstructured":"Aleksandrova LR, Phillips AG (2021) Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci 42(11):929\u2013942","journal-title":"Trends Pharmacol Sci"},{"key":"5519_CR16","doi-asserted-by":"crossref","unstructured":"Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G et al (2023) The Bright side of Psychedelics: latest advances and challenges in Neuropharmacology. Int J Mol Sci. 24(2)","DOI":"10.3390\/ijms24021329"},{"issue":"2","key":"5519_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s10865-021-00267-1","volume":"45","author":"LG Perez","year":"2022","unstructured":"Perez LG, Siconolfi D, Troxel WM, Tucker JS, Seelam R, Rodriguez A et al (2022) Loneliness and multiple health domains: associations among emerging adults. J Behav Med 45(2):260\u2013271","journal-title":"J Behav Med"},{"issue":"1","key":"5519_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/jpet.122.001318","volume":"384","author":"DR Maguire","year":"2023","unstructured":"Maguire DR (2023) Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus monkeys. J Pharmacol Exp Ther 384(1):155\u2013162","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR19","unstructured":"Weleff J, Pulido-Saavedra A, Anand A, Nero N, Nia AB (2023) CRD42023392307 Angarita. GA. The therapeutic effects of psychedelics for opioid use disorder: a systematic review of clinical studies. PROSPERO 2024"},{"issue":"1","key":"5519_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamapsychiatry.2022.4020","volume":"80","author":"BD Kiluk","year":"2023","unstructured":"Kiluk BD, Kleykamp BA, Comer SD, Griffiths RR, Huhn AS, Johnson MW et al (2023) Clinical Trial Design challenges and opportunities for emerging treatments for opioid use disorder: a review. JAMA Psychiatry 80(1):84\u201392","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"5519_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2023.1968","volume":"80","author":"ND Volkow","year":"2023","unstructured":"Volkow ND, Gordon JA, Wargo EM (2023) Psychedelics as therapeutics-potential and challenges. JAMA Psychiatry 80(10):979\u2013980","journal-title":"JAMA Psychiatry"},{"key":"5519_CR22","unstructured":"(CDER) Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry DRAFT GUIDANCE www.fda.gov2023 updated 06\/26\/2023; cited 2024. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations"},{"issue":"4","key":"5519_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00406-021-01267-7","volume":"272","author":"LS Rodrigues","year":"2022","unstructured":"Rodrigues LS, Rossi GN, Rocha JM, F LO, Bouso JC, Hallak JEC et al (2022) Effects of Ayahuasca and its alkaloids on substance use disorders: an updated (2016\u20132020) systematic review of preclinical and human studies. Eur Arch Psychiatry Clin Neurosci 272(4):541\u2013556","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"5519_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00702-024-02757-3","volume":"131","author":"FF Hilal","year":"2024","unstructured":"Hilal FF, Jeanblanc J, Deschamps C, Naassila M, Pierrefiche O, Ben Hamida S (2024) Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies. J Neural Transm (Vienna) 131(5):525\u2013561","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"5519_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1055\/a-1341-1907","volume":"54","author":"LJ Mertens","year":"2021","unstructured":"Mertens LJ, Preller KH (2021) Classical psychedelics as therapeutics in Psychiatry - Current Clinical evidence and potential therapeutic mechanisms in Substance Use and Mood disorders. Pharmacopsychiatry 54(4):176\u2013190","journal-title":"Pharmacopsychiatry"},{"key":"5519_CR26","doi-asserted-by":"publisher","first-page":"1221719","DOI":"10.3389\/fphar.2023.1221719","volume":"14","author":"MG Hornick","year":"2023","unstructured":"Hornick MG, Stefanski A (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Front Pharmacol 14:1221719","journal-title":"Front Pharmacol"},{"issue":"10","key":"5519_CR27","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L et al (2020) Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synthesis 18(10):2119\u20132126","journal-title":"JBI Evid Synthesis"},{"issue":"7","key":"5519_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169(7):467\u2013473","journal-title":"Ann Intern Med"},{"key":"5519_CR29","unstructured":"Saavedra AP, Oliva HNP, Kitaneh R, Funaro MC, Angarita GA (2023) Effects of Psychedelics on opioid use disorder. Protocol for a Scoping Review of Preclinical Studies"},{"issue":"1","key":"5519_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1258\/la.2011.011087","volume":"46","author":"M Leenaars","year":"2012","unstructured":"Leenaars M, Hooijmans CR, van Veggel N, ter Riet G, Leeflang M, Hooft L et al (2012) A step-by-step guide to systematically identify all relevant animal studies. Lab Anim 46(1):24\u201331","journal-title":"Lab Anim"},{"key":"5519_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C (2016) PRESS peer review of electronic search strategies: 2015 Guideline Statement. J Clin Epidemiol 75:40\u201346","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"5519_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE, Psychedelics (2016) Pharmacol Rev 68(2):264\u2013355","journal-title":"Pharmacol Rev"},{"issue":"1","key":"5519_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol 14(1):43","journal-title":"BMC Med Res Methodol"},{"key":"5519_CR34","unstructured":"MapChart (2024) Available from: https:\/\/www.mapchart.net\/about.html"},{"issue":"1","key":"5519_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0924-977X(93)90291-S","volume":"3","author":"PJ Brent","year":"1993","unstructured":"Brent PJ, Chahl LA (1993) Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites. Eur Neuropsychopharmacol 3(1):23\u201332","journal-title":"Eur Neuropsychopharmacol"},{"key":"5519_CR36","first-page":"64","volume":"294","author":"ED Dzoljic","year":"1988","unstructured":"Dzoljic ED, Kaplan CD, Dzoljic MR (1988) Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. Arch Int Pharmacodyn Ther 294:64\u201370","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"3","key":"5519_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0014-2999(91)90474-5","volume":"195","author":"SD Glick","year":"1991","unstructured":"Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (1991) Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 195(3):341\u2013345","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"5519_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0028-3908(92)90089-8","volume":"31","author":"SD Glick","year":"1992","unstructured":"Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN (1992) Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology 31(5):497\u2013500","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"5519_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/0006-8993(95)01563-9","volume":"713","author":"SD Glick","year":"1996","unstructured":"Glick SD, Pearl SM, Cai J, Maisonneuve IM (1996) Ibogaine-like effects of noribogaine in rats. Brain Res 713(1\u20132):294\u2013297","journal-title":"Brain Res"},{"issue":"1\u20132","key":"5519_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0006-8993(96)00056-X","volume":"719","author":"SD Glick","year":"1996","unstructured":"Glick SD, Kuehne ME, Maisonneuve IM, Bandarage UK, Molinari HH (1996) 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res 719(1\u20132):29\u201335","journal-title":"Brain Res"},{"issue":"2","key":"5519_CR41","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0006-8993(96)01414-X","volume":"749","author":"SD Glick","year":"1997","unstructured":"Glick SD, Maisonneuve IM, Pearl SM (1997) Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res 749(2):340\u2013343","journal-title":"Brain Res"},{"issue":"1","key":"5519_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1749-6632.1998.tb08237.x","volume":"844","author":"SD Glick","year":"1998","unstructured":"Glick SD, Maisonneuve IM (1998) Mechanisms of antiaddictive actions of Ibogainea. Ann N Y Acad Sci 844(1):214\u2013226","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"5519_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0014-2999(97)01099-6","volume":"332","author":"P Gonz\u00e1lez","year":"1997","unstructured":"Gonz\u00e1lez P, Cabello P, Germany A, Norris B, Contreras E (1997) Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur J Pharmacol 332(3):257\u2013262","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"5519_CR44","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s11064-004-6884-y","volume":"29","author":"D Ji","year":"2004","unstructured":"Ji D, Sui ZY, Ma YY, Luo F, Cui CL, Han JS (2004) NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem Res 29(11):2113\u20132120","journal-title":"Neurochem Res"},{"issue":"3","key":"5519_CR45","doi-asserted-by":"publisher","first-page":"e12926","DOI":"10.1111\/adb.12926","volume":"26","author":"DA Martin","year":"2021","unstructured":"Martin DA, Gyawali U, Calu DJ (2021) Effects of 5-HT(2A) receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats. Addict Biol 26(3):e12926","journal-title":"Addict Biol"},{"issue":"7","key":"5519_CR46","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1177\/0269881116641331","volume":"30","author":"DC Mash","year":"2016","unstructured":"Mash DC, Ameer B, Prou D, Howes JF, Maillet EL (2016) Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. J Psychopharmacol 30(7):688\u2013697","journal-title":"J Psychopharmacol"},{"key":"5519_CR47","doi-asserted-by":"publisher","first-page":"582147","DOI":"10.3389\/fnbeh.2020.582147","volume":"14","author":"G McKendrick","year":"2020","unstructured":"McKendrick G, Graziane NM (2020) Drug-Induced Conditioned Place Preference and its practical use in Substance Use Disorder Research. Front Behav Neurosci 14:582147","journal-title":"Front Behav Neurosci"},{"issue":"1","key":"5519_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0167-0115(94)90378-6","volume":"54","author":"SLT Cappendijk","year":"1994","unstructured":"Cappendijk SLT, Fekkes D, Dzoljic MR (1994) Norharman \u2014 endogenous inhibitor of morphine withdrawal. Regul Pept 54(1):39\u201340","journal-title":"Regul Pept"},{"issue":"1","key":"5519_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0166-4328(94)90080-9","volume":"65","author":"SL Cappendijk","year":"1994","unstructured":"Cappendijk SL, Fekkes D, Dzoljic MR (1994) The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine. Behav Brain Res 65(1):117\u2013119","journal-title":"Behav Brain Res"},{"issue":"3","key":"5519_CR50","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0091-3057(03)00119-9","volume":"75","author":"IM Maisonneuve","year":"2003","unstructured":"Maisonneuve IM, Glick SD (2003) Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 75(3):607\u2013618","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20133","key":"5519_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejphar.2005.09.060","volume":"525","author":"V Panchal","year":"2005","unstructured":"Panchal V, Taraschenko OD, Maisonneuve IM, Glick SD (2005) Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. Eur J Pharmacol 525(1\u20133):98\u2013104","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"5519_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0278-5846(01)00268-8","volume":"26","author":"LA Parke","year":"2002","unstructured":"Parke LA, Burton P, McDonald RV, Kim JA, Siegel S (2002) Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine. Prog Neuropsychopharmacol Biol Psychiatry 26(2):293\u2013297","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"5519_CR53","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/00001756-199805110-00004","volume":"9","author":"B Rho","year":"1998","unstructured":"Rho B, Glick SD (1998) Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. NeuroReport 9(7):1283\u20131285","journal-title":"NeuroReport"},{"issue":"1","key":"5519_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00001756-199009000-00005","volume":"1","author":"LG Sharpe","year":"1990","unstructured":"Sharpe LG, Jaffe JH (1990) Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat. NeuroReport 1(1):17\u201319","journal-title":"NeuroReport"},{"issue":"4","key":"5519_CR55","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0024-3205(00)00639-1","volume":"67","author":"T Suzuki","year":"2000","unstructured":"Suzuki T, Kato H, Aoki T, Tsuda M, Narita M, Misawa M (2000) Effects of the non-competitive NMDA receptor antagonist ketamine on morphine-induced place preference in mice. Life Sci 67(4):383\u2013389","journal-title":"Life Sci"},{"key":"5519_CR56","doi-asserted-by":"publisher","first-page":"172927","DOI":"10.1016\/j.pbb.2020.172927","volume":"194","author":"JM Witkin","year":"2020","unstructured":"Witkin JM, Kranzler J, Kaniecki K, Popik P, Smith JL, Hashimoto K et al (2020) R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder(1). Pharmacol Biochem Behav 194:172927","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"5519_CR57","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF02246099","volume":"117","author":"SI Dworkin","year":"1995","unstructured":"Dworkin SI, Gleeson S, Meloni D, Koves TR, Martin TJ (1995) Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats. Psychopharmacology 117(3):257\u2013261","journal-title":"Psychopharmacology"},{"issue":"1","key":"5519_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.cr.7290148","volume":"13","author":"C Gao","year":"2003","unstructured":"Gao C, Che LW, Chen J, Xu XJ, Chi ZQ (2003) Ohmefentanyl stereoisomers induce changes of CREB phosphorylation in hippocampus of mice in conditioned place preference paradigm. Cell Res 13(1):29\u201334","journal-title":"Cell Res"},{"issue":"1\u20132","key":"5519_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-2999(02)01284-0","volume":"438","author":"SD Glick","year":"2002","unstructured":"Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW (2002) Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 438(1\u20132):99\u2013105","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"5519_CR60","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejphar.2006.03.045","volume":"537","author":"SD Glick","year":"2006","unstructured":"Glick SD, Ramirez RL, Livi JM, Maisonneuve IM (2006) 18-Methoxycoronaridine acts in the medial habenula and\/or interpeduncular nucleus to decrease morphine self-administration in rats. Eur J Pharmacol 537(1\u20133):94\u201398","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"5519_CR61","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0960-894X(00)00033-0","volume":"10","author":"CH King","year":"2000","unstructured":"King CH, Meckler H, Herr RJ, Trova MP, Glick SD, Maisonneuve IM (2000) Synthesis of enantiomerically pure (+)- and (-)-18-methoxycoronaridine hydrochloride and their preliminary assessment as anti-addictive agents. Bioorg Med Chem Lett 10(5):473\u2013476","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"5519_CR62","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0091-3057(91)90130-T","volume":"39","author":"H Koyuncuo\u011flu","year":"1991","unstructured":"Koyuncuo\u011flu H, Aricio\u011flu F (1991) Previous chronic blockade of NMDA receptors intensifies morphine dependence in rats. Pharmacol Biochem Behav 39(3):575\u2013579","journal-title":"Pharmacol Biochem Behav"},{"issue":"5","key":"5519_CR63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0278-5846(03)00109-X","volume":"27","author":"MB Leal","year":"2003","unstructured":"Leal MB, Michelin K, Souza DO, Elisabetsky E (2003) Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors. Prog Neuropsychopharmacol Biol Psychiatry 27(5):781\u2013785","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"5519_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0014-2999(99)00560-9","volume":"383","author":"IM Maisonneuve","year":"1999","unstructured":"Maisonneuve IM, Glick SD (1999) Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine. Eur J Pharmacol 383(1):15\u201321","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"5519_CR65","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/ejn.13572","volume":"45","author":"H Vargas-Perez","year":"2017","unstructured":"Vargas-Perez H, Grieder TE, Ting AKR, Maal-Bared G, Chwalek M, van der Kooy D (2017) A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents. Eur J Neurosci 45(11):1410\u20131417","journal-title":"Eur J Neurosci"},{"issue":"2","key":"5519_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0278-5846(01)00268-8","volume":"26","author":"LA Parker","year":"2002","unstructured":"Parker LA, Burton P, McDonald RV, Kim JA, Siegel S (2002) Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine. Prog Neuropsychopharmacol Biol Psychiatry 26(2):293\u2013297","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"5519_CR67","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00213-012-2803-0","volume":"225","author":"DR Maguire","year":"2013","unstructured":"Maguire DR, Li JX, Koek W, France CP (2013) Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys. Psychopharmacology 225(1):173\u2013185","journal-title":"Psychopharmacology"},{"issue":"5","key":"5519_CR68","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/0278-5846(96)00064-4","volume":"20","author":"T Luxton","year":"1996","unstructured":"Luxton T, Parker LA, Siegel S (1996) Ibogaine fails to interrupt the expression of a previously established one-trial morphine place preference. Prog Neuropsychopharmacol Biol Psychiatry 20(5):857\u2013872","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"5519_CR69","unstructured":"Bohlul Habibi Asl Kambiz Hassanzadeh (2004) Effects of ketamine and midazolam on morphine induced dependence and tolerance in mice. DARU, J Pharm Sci 12(3):101"},{"issue":"5","key":"5519_CR70","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0024-3205(01)01429-1","volume":"70","author":"E Streel","year":"2001","unstructured":"Streel E, Dan B, Bredas P, Clement B, Pelc I, Verbanck P (2001) Interference with withdrawal signs of naloxone-induced opiate withdrawal under anesthesia is anesthetic-specific in opiate-dependent rats. Life Sci 70(5):517\u2013522","journal-title":"Life Sci"},{"key":"5519_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnbeh.2020.00075","volume":"14","author":"G McKendrick","year":"2020","unstructured":"McKendrick G, Garrett H, Jones HE, McDevitt DS, Sharma S, Silberman Y et al (2020) Ketamine blocks Morphine-Induced conditioned place preference and anxiety-like behaviors in mice. Front Behav Neurosci 14:75","journal-title":"Front Behav Neurosci"},{"issue":"3","key":"5519_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FBP.0b013e3282fe88a0","volume":"19","author":"H Zhai","year":"2008","unstructured":"Zhai H, Wu P, Chen S, Li F, Liu Y, Lu L (2008) Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats. Behav Pharmacol 19(3):211\u2013216","journal-title":"Behav Pharmacol"},{"issue":"2","key":"5519_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1460-9568.1993.tb00479.x","volume":"5","author":"K Chergui","year":"1993","unstructured":"Chergui K, Charl\u00e9ty PJ, Akaoka H, Saunier CF, Brunet JL, Buda M et al (1993) Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5(2):137\u2013144","journal-title":"Eur J Neurosci"},{"issue":"44","key":"5519_CR74","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","volume":"36","author":"CF Zorumski","year":"2016","unstructured":"Zorumski CF, Izumi Y, Mennerick S (2016) Ketamine: NMDA receptors and Beyond. J Neurosci 36(44):11158\u201311164","journal-title":"J Neurosci"},{"key":"5519_CR75","doi-asserted-by":"publisher","first-page":"593860","DOI":"10.3389\/fnbeh.2020.593860","volume":"14","author":"CE Strong","year":"2020","unstructured":"Strong CE, Kabbaj M (2020) Neural mechanisms underlying the rewarding and therapeutic effects of ketamine as a treatment for Alcohol Use Disorder. Front Behav Neurosci 14:593860","journal-title":"Front Behav Neurosci"},{"key":"5519_CR76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsat.2019.10.003","volume":"107","author":"AM Elias","year":"2019","unstructured":"Elias AM, Pepin MJ, Brown JN (2019) Adjunctive memantine for opioid use disorder treatment: a systematic review. J Subst Abuse Treat 107:38\u201343","journal-title":"J Subst Abuse Treat"},{"key":"5519_CR77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neubiorev.2020.04.024","volume":"114","author":"E Galaj","year":"2020","unstructured":"Galaj E, Newman AH, Xi ZX (2020) Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges. Neurosci Biobehav Rev 114:38\u201352","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"5519_CR78","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3(8):760\u2013773","journal-title":"Lancet Psychiatry"},{"key":"5519_CR79","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","volume":"142","author":"I Ivan Ezquerra-Romano","year":"2018","unstructured":"Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA (2018) Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology 142:72\u201382","journal-title":"Neuropharmacology"},{"key":"5519_CR80","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neuropharm.2018.06.008","volume":"142","author":"R Ingram","year":"2018","unstructured":"Ingram R, Kang H, Lightman S, Jane DE, Bortolotto ZA, Collingridge GL et al (2018) Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity. Neuropharmacology 142:30\u201340","journal-title":"Neuropharmacology"},{"issue":"1","key":"5519_CR81","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","volume":"224","author":"H Koike","year":"2011","unstructured":"Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224(1):107\u2013111","journal-title":"Behav Brain Res"},{"issue":"8","key":"5519_CR82","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","volume":"162","author":"PW Kalivas","year":"2005","unstructured":"Kalivas PW, Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162(8):1403\u20131413","journal-title":"Am J Psychiatry"},{"issue":"1","key":"5519_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.physbeh.2005.06.018","volume":"86","author":"AE Kelley","year":"2005","unstructured":"Kelley AE, Schiltz CA, Landry CF (2005) Neural systems recruited by drug- and food-related cues: studies of gene activation in corticolimbic regions. Physiol Behav 86(1):11\u201314","journal-title":"Physiol Behav"},{"key":"5519_CR84","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pnpbp.2017.05.009","volume":"87","author":"AMW Taylor","year":"2018","unstructured":"Taylor AMW (2018) Corticolimbic circuitry in the modulation of chronic pain and substance abuse. Prog Neuropsychopharmacol Biol Psychiatry 87:263\u2013268","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"5519_CR85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0014-2999(03)01971-X","volume":"474","author":"GJ Marek","year":"2003","unstructured":"Marek GJ (2003) Behavioral evidence for \u00b5-opioid and 5-HT2A receptor interactions. Eur J Pharmacol 474(1):77\u201383","journal-title":"Eur J Pharmacol"},{"key":"5519_CR86","doi-asserted-by":"crossref","unstructured":"Gumpper RH, Roth BL (2023) Psychedelics: preclinical insights provide directions for future research. Neuropsychopharmacol 49(1):119\u2013127","DOI":"10.1038\/s41386-023-01567-7"},{"key":"5519_CR87","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","volume":"277","author":"AL Halberstadt","year":"2015","unstructured":"Halberstadt AL (2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 277:99\u2013120","journal-title":"Behav Brain Res"},{"issue":"11","key":"5519_CR88","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH (2020) Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 21(11):611\u2013624","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"5519_CR89","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE, Hallucinogens (2004) Pharmacol Ther 101(2):131\u2013181","journal-title":"Pharmacol Ther"},{"issue":"17","key":"5519_CR90","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s00213-017-4653-2","volume":"234","author":"LF Berro","year":"2017","unstructured":"Berro LF, Perez Diaz M, Maltbie E, Howell LL (2017) Effects of the serotonin 2\u00a0C receptor agonist WAY163909 on the abuse-related effects and mesolimbic dopamine neurochemistry induced by abused stimulants in rhesus monkeys. Psychopharmacology 234(17):2607\u20132617","journal-title":"Psychopharmacology"},{"issue":"1","key":"5519_CR91","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40473-022-00246-z","volume":"9","author":"H Hadizadeh","year":"2022","unstructured":"Hadizadeh H, Flores J, Nunes E, Mayerson T, Potenza MN, Angarita GA (2022) Novel pharmacological agents for the treatment of Cocaine Use Disorder. Curr Behav Neurosci Rep 9(1):27\u201346","journal-title":"Curr Behav Neurosci Rep"},{"issue":"10","key":"5519_CR92","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tips.2013.08.001","volume":"34","author":"GA Higgins","year":"2013","unstructured":"Higgins GA, Sellers EM, Fletcher PJ (2013) From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends Pharmacol Sci 34(10):560\u2013570","journal-title":"Trends Pharmacol Sci"},{"key":"5519_CR93","doi-asserted-by":"publisher","first-page":"1197890","DOI":"10.3389\/fpsyt.2023.1197890","volume":"14","author":"S Zhornitsky","year":"2023","unstructured":"Zhornitsky S, Oliva HNP, Jayne LA, Allsop ASA, Kaye AP, Potenza MN et al (2023) Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review. Front Psychiatry 14:1197890","journal-title":"Front Psychiatry"},{"issue":"11","key":"5519_CR94","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC et al (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23(11):3170\u20133182","journal-title":"Cell Rep"},{"issue":"4","key":"5519_CR95","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41380-022-01465-2","volume":"27","author":"SE Holmes","year":"2022","unstructured":"Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K et al (2022) Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry 27(4):2273\u20132281","journal-title":"Mol Psychiatry"},{"key":"5519_CR96","doi-asserted-by":"crossref","unstructured":"Oliva HNP, Prudente TP, Nunes EJ, Cosgrove KP, Radhakrishnan R, Potenza MN, Angarita GA (2024) Substance use and spine density: a systematic review and meta-analysis of preclinical studies. Mol Psychiatry 29(9):2873\u20132885","DOI":"10.1038\/s41380-024-02519-3"},{"issue":"4","key":"5519_CR97","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/syn.10146","volume":"46","author":"TE Robinson","year":"2002","unstructured":"Robinson TE, Gorny G, Savage VR, Kolb B (2002) Widespread but regionally specific effects of experimenter- versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats. Synapse 46(4):271\u2013279","journal-title":"Synapse"},{"issue":"11","key":"5519_CR98","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1038\/npp.2016.69","volume":"41","author":"AK Fakira","year":"2016","unstructured":"Fakira AK, Massaly N, Cohensedgh O, Berman A, Mor\u00f3n JA (2016) Morphine-Associated Contextual cues Induce Structural plasticity in hippocampal CA1 pyramidal neurons. Neuropsychopharmacology 41(11):2668\u20132678","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"5519_CR99","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1083\/jcb.201605065","volume":"215","author":"Y Cai","year":"2016","unstructured":"Cai Y, Yang L, Hu G, Chen X, Niu F, Yuan L et al (2016) Regulation of morphine-induced synaptic alterations: role of oxidative stress, ER stress, and autophagy. J Cell Biol 215(2):245\u2013258","journal-title":"J Cell Biol"},{"key":"5519_CR100","doi-asserted-by":"crossref","unstructured":"Volkow ND, Gordon JA, Wargo EM (2023) Psychedelics as therapeutics-potential and challenges. JAMA Psychiatry 80(10):979\u2013980","DOI":"10.1001\/jamapsychiatry.2023.1968"},{"issue":"3","key":"5519_CR101","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","volume":"50","author":"BJ Malcolm","year":"2018","unstructured":"Malcolm BJ, Polanco M, Barsuglia JP (2018) Changes in Withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. J Psychoact Drugs 50(3):256\u2013265","journal-title":"J Psychoact Drugs"},{"issue":"3","key":"5519_CR102","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/105504999305848","volume":"8","author":"KR Alper","year":"1999","unstructured":"Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999) Treatment of acute opioid withdrawal with ibogaine. Am J Addict 8(3):234\u2013242","journal-title":"Am J Addict"},{"issue":"4","key":"5519_CR103","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","volume":"23","author":"E Krupitsky","year":"2002","unstructured":"Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A (2002) Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 23(4):273\u2013283","journal-title":"J Subst Abuse Treat"},{"key":"5519_CR104","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0099-9598(01)56012-5","volume":"56","author":"DC Mash","year":"2001","unstructured":"Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD et al (2001) Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol 56:155\u2013171","journal-title":"Alkaloids Chem Biol"},{"issue":"2","key":"5519_CR105","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1556\/2054.01.2017.009","volume":"1","author":"AK Davis","year":"2017","unstructured":"Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M (2017) Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. J Psychedelic Stud 1(2):65\u201373","journal-title":"J Psychedelic Stud"},{"issue":"1","key":"5519_CR106","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","volume":"44","author":"TK Brown","year":"2018","unstructured":"Brown TK, Alper K (2018) Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse 44(1):24\u201336","journal-title":"Am J Drug Alcohol Abuse"},{"key":"5519_CR107","doi-asserted-by":"crossref","unstructured":"Brown T (2013) Ibogaine in the treatment of Substance Dependence. Curr Drug Abuse Rev. 6","DOI":"10.2174\/15672050113109990001"},{"key":"5519_CR108","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fphar.2018.00529","volume":"9","author":"DC Mash","year":"2018","unstructured":"Mash DC, Duque L, Page B, Allen-Ferdinand K (2018) Ibogaine Detoxification transitions Opioid and Cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Front Pharmacol 9:529","journal-title":"Front Pharmacol"},{"issue":"1","key":"5519_CR109","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","volume":"44","author":"GE Noller","year":"2018","unstructured":"Noller GE, Frampton CM, Yazar-Klosinski B (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse 44(1):37\u201346","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"5519_CR110","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","volume":"39","author":"EM Krupitsky","year":"2007","unstructured":"Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoact Drugs 39(1):13\u201319","journal-title":"J Psychoact Drugs"},{"issue":"12","key":"5519_CR111","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00228-001-0405-6","volume":"57","author":"BG Reigner","year":"2002","unstructured":"Reigner BG, Blesch KS (2002) Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol 57(12):835\u2013845","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"5519_CR112","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27\u201331","journal-title":"J Basic Clin Pharm"},{"issue":"4","key":"5519_CR113","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1367-5931(00)00228-3","volume":"5","author":"PR Chaturvedi","year":"2001","unstructured":"Chaturvedi PR, Decker CJ, Odinecs A (2001) Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol 5(4):452\u2013463","journal-title":"Curr Opin Chem Biol"},{"issue":"6","key":"5519_CR114","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1080\/10807030600977269","volume":"12","author":"LR Rhomberg","year":"2006","unstructured":"Rhomberg LR, Lewandowski TA (2006) Methods for identifying a default cross-species scaling factor. Hum Ecol Risk Assessment: Int J 12(6):1094\u20131127","journal-title":"Hum Ecol Risk Assessment: Int J"},{"issue":"12","key":"5519_CR115","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1111\/j.1360-0443.2007.02011.x","volume":"102","author":"LV Panlilio","year":"2007","unstructured":"Panlilio LV, Goldberg SR (2007) Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102(12):1863\u20131870","journal-title":"Addiction"},{"issue":"2","key":"5519_CR116","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1124\/jpet.119.258004","volume":"371","author":"KE Dunn","year":"2019","unstructured":"Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM (2019) Non-opioid Neurotransmitter Systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence. J Pharmacol Exp Ther 371(2):422\u2013452","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"5519_CR117","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1526-4637.2010.00881.x","volume":"11","author":"J Shurman","year":"2010","unstructured":"Shurman J, Koob GF, Gutstein HB (2010) Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med 11(7):1092\u20131098","journal-title":"Pain Med"},{"issue":"1","key":"5519_CR118","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","volume":"87","author":"GF Koob","year":"2020","unstructured":"Koob GF (2020) Neurobiology of opioid addiction: opponent process, Hyperkatifeia, and negative reinforcement. Biol Psychiatry 87(1):44\u201353","journal-title":"Biol Psychiatry"},{"key":"5519_CR119","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/7854_2021_288","volume":"58","author":"GF Koob","year":"2022","unstructured":"Koob GF (2022) Anhedonia, Hyperkatifeia, and negative reinforcement in Substance Use disorders. Curr Top Behav Neurosci 58:147\u2013165","journal-title":"Curr Top Behav Neurosci"},{"issue":"5","key":"5519_CR120","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/jcpt.13114","volume":"45","author":"JV Pergolizzi Jr","year":"2020","unstructured":"Pergolizzi JV Jr., Raffa RB, Rosenblatt MH (2020) Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther 45(5):892\u2013903","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"5519_CR121","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00213-005-2155-0","volume":"178","author":"AC Harris","year":"2005","unstructured":"Harris AC, Gewirtz JC (2005) Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal. Psychopharmacology 178(4):353\u2013366","journal-title":"Psychopharmacology"},{"issue":"1","key":"5519_CR122","first-page":"170","volume":"2016","author":"RL Perlman","year":"2016","unstructured":"Perlman RL (2016) Mouse models of human disease: an evolutionary perspective. Evol Med Public Health 2016(1):170\u2013176","journal-title":"Evol Med Public Health"},{"issue":"6915","key":"5519_CR123","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nature01262","volume":"420","author":"RH Waterston","year":"2002","unstructured":"Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P et al (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420(6915):520\u2013562","journal-title":"Nature"},{"issue":"3","key":"5519_CR124","first-page":"207","volume":"110","author":"EC Bryda","year":"2013","unstructured":"Bryda EC (2013) The mighty mouse: the impact of rodents on advances in biomedical research. Mo Med 110(3):207\u2013211","journal-title":"Mo Med"},{"issue":"10","key":"5519_CR125","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1242\/dmm.026120","volume":"9","author":"B Ellenbroek","year":"2016","unstructured":"Ellenbroek B, Youn J (2016) Rodent models in neuroscience research: is it a rat race? Dis Model Mech 9(10):1079\u20131087","journal-title":"Dis Model Mech"},{"issue":"6","key":"5519_CR126","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.neuron.2014.06.003","volume":"82","author":"PR Roelfsema","year":"2014","unstructured":"Roelfsema PR, Treue S (2014) Basic neuroscience research with nonhuman primates: a small but indispensable component of biomedical research. Neuron 82(6):1200\u20131204","journal-title":"Neuron"},{"issue":"1","key":"5519_CR127","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5194\/asr-5-11-2010","volume":"5","author":"MJ Prescott","year":"2010","unstructured":"Prescott MJ (2010) Ethics of primate use. Adv Sci Res 5(1):11\u201322","journal-title":"Adv Sci Res"},{"issue":"1","key":"5519_CR128","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s42826-022-00124-5","volume":"38","author":"O Go\u00f1i-Balentziaga","year":"2022","unstructured":"Go\u00f1i-Balentziaga O, Ortega-Saez I, Vila S, Azkona G (2022) A survey on the use of mice, pigs, dogs and monkeys as animal models in biomedical research in Spain. Lab Anim Res 38(1):14","journal-title":"Lab Anim Res"},{"key":"5519_CR129","doi-asserted-by":"crossref","unstructured":"Lopresti-Goodman SM, Villatoro-Sorto B (2022) The benefits and challenges of conducting Primate Research in different settings. Anim (Basel). 13(1)","DOI":"10.3390\/ani13010133"},{"key":"5519_CR130","unstructured":"Towers EB, Williams IL, Qillawala EI, Rissman EF, Lynch WJ Sex\/Gender differences in the Time-Course for the development of Substance Use Disorder: a focus on the Telescoping Effect. Pharmacological Reviews. 2022:PHARMREV-AR-2021-000361."},{"issue":"1","key":"5519_CR131","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ (2020) Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ 11(1):32","journal-title":"Biol Sex Differ"},{"issue":"2","key":"5519_CR132","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.psc.2010.01.004","volume":"33","author":"SF Greenfield","year":"2010","unstructured":"Greenfield SF, Back SE, Lawson K, Brady KT (2010) Substance abuse in women. Psychiatr Clin North Am 33(2):339\u2013355","journal-title":"Psychiatr Clin North Am"},{"issue":"2","key":"5519_CR133","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR (2021) The subjective effects of Psychedelics are necessary for their Enduring Therapeutic effects. ACS Pharmacol Translational Sci 4(2):568\u2013572","journal-title":"ACS Pharmacol Translational Sci"},{"issue":"2","key":"5519_CR134","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2021","unstructured":"Olson DE (2021) The subjective effects of Psychedelics May not be necessary for their Enduring Therapeutic effects. ACS Pharmacol Transl Sci 4(2):563\u2013567","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"5519_CR135","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abus 43(1):55\u201360","journal-title":"Am J Drug Alcohol Abus"},{"issue":"10","key":"5519_CR136","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E et al (2022) Percentage of Heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with Alcohol Use Disorder: a Randomized Clinical Trial. JAMA Psychiatry 79(10):953\u2013962","journal-title":"JAMA Psychiatry"},{"issue":"7842","key":"5519_CR137","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y et al (2021) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589(7842):474\u2013479","journal-title":"Nature"},{"key":"5519_CR138","doi-asserted-by":"publisher","first-page":"e00196","DOI":"10.1016\/j.mec.2022.e00196","volume":"14","author":"AM Adams","year":"2022","unstructured":"Adams AM, Anas NA, Sen AK, Hinegardner-Hendricks JD, O\u2019Dell PJ, Gibbons WJ Jr. et al (2022) Development of an E. coli-based norbaeocystin production platform and evaluation of behavioral effects in rats. Metab Eng Commun 14:e00196","journal-title":"Metab Eng Commun"},{"key":"5519_CR139","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","volume":"263","author":"EE Acevedo-Diaz","year":"2020","unstructured":"Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Zarate CA et al (2020) Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord 263:568\u2013575","journal-title":"J Affect Disord"},{"issue":"5","key":"5519_CR140","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M et al (2021) Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an International Expert Opinion on the available evidence and implementation. Am J Psychiatry 178(5):383\u2013399","journal-title":"Am J Psychiatry"},{"issue":"12","key":"5519_CR141","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","volume":"79","author":"TG Rhee","year":"2022","unstructured":"Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI et al (2022) Efficacy and Safety of Ketamine vs electroconvulsive therapy among patients with Major Depressive Episode: a systematic review and Meta-analysis. JAMA Psychiatry 79(12):1162\u20131172","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"5519_CR142","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/add.15448","volume":"117","author":"T Knuijver","year":"2022","unstructured":"Knuijver T, Schellekens A, Belgers M, Donders R, van Oosteren T, Kramers K et al (2022) Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction 117(1):118\u2013128","journal-title":"Addiction"},{"issue":"1","key":"5519_CR143","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1527-3458.1999.tb00084.x","volume":"5","author":"SD Glick","year":"1999","unstructured":"Glick SD, Maisonneuve IM, Hough LB, Kuehne ME, Bandarage UK (1999) (\u00b1)-18-Methoxycoronaridine: a Novel Iboga Alkaloid Congener having potential anti-addictive efficacy. CNS Drug Rev 5(1):27\u201342","journal-title":"CNS Drug Rev"},{"key":"5519_CR144","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.3402\/ehtj.v4i0.7107","volume":"4","author":"SS Kalsi","year":"2011","unstructured":"Kalsi SS, Wood DM, Dargan PI (2011) The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J 4:7107","journal-title":"Emerg Health Threats J"},{"issue":"2","key":"5519_CR145","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12094","volume":"77","author":"M Niesters","year":"2014","unstructured":"Niesters M, Martini C, Dahan A (2014) Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 77(2):357\u2013367","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"5519_CR146","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40429-022-00432-9","volume":"9","author":"B Martins","year":"2022","unstructured":"Martins B, Rutland W, De Aquino JP, Kazer BL, Funaro M, Potenza MN et al (2022) Helpful or harmful? The therapeutic potential of medications with varying degrees of abuse liability in the treatment of Substance Use disorders. Curr Addict Rep 9(4):647\u2013659","journal-title":"Curr Addict Rep"},{"issue":"Pt 1","key":"5519_CR147","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","volume":"126","author":"Y Liu","year":"2016","unstructured":"Liu Y, Lin D, Wu B, Zhou W (2016) Ketamine abuse potential and use disorder. Brain Res Bull 126(Pt 1):68\u201373","journal-title":"Brain Res Bull"},{"issue":"4","key":"5519_CR148","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0376-8716(84)90005-X","volume":"13","author":"DE Hunt","year":"1984","unstructured":"Hunt DE, Lipton DS, Goldsmith D, Strug D (1984) Street pharmacology: uses of cocaine and heroin in the treatment of addiction. Drug Alcohol Depend 13(4):375\u2013387","journal-title":"Drug Alcohol Depend"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05519-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05519-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05519-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T22:55:16Z","timestamp":1737413716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05519-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":148,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5519"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05519-2","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed manuscript and provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bassir Nia is a member of the Scientific Advisory Board of Synendos Therapeutics AG, Switzerland.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}